Answers are grounded in this paper and cite their sources.
Stereotactic radiosurgery (SRS) is increasingly used to treat benign spinal cord tumors. However, standardized guidelines and data on outcomes are lacking. This review aimed to establish clearer guidelines for using SRS to treat meningiomas, schwannomas, and neurofibromas. The analysis included 15 studies, encompassing 616 patients with 707 benign spinal lesions. The cervical spine was the most common treatment site (46.2%), followed by the lumbar, thoracic, and sacral regions. Minimum doses ranged from 10 to 16 Gy, while maximum doses spanned from 15 to 33 Gy, delivered in 1 to 5 fractions. No significant difference was found in the mean single SRS dose among the three common pathologies (p=0.968). The local tumor control rate exceeded 90%. Pain improved in 12–100% of patients and remained stable in 0–88% of patients after SRS. Many patients had received prior surgical (0–77.7%) or radiotherapy (0–85%) treatments before undergoing SRS, highlighting the role of this modality as a secondary treatment option. The spinal side effects of SRS were minimal, with a complication rate of 1.4%. SRS is a safe and effective treatment for benign spinal tumors, demonstrating high rates of local control and pain relief with minimal complications. Schwannomas, meningiomas, and neurofibromas were the most commonly treated tumors, and SRS was frequently used as a secondary option following surgery or radiotherapy. Hypofractionation is suggested to reduce tissue exposure, but an optimal fractionation schedule has yet to be determined. Further research is needed to refine SRS protocols and reduce treatment-related complications.
No takes yet. Share an insight, caveat, or question.
Mosleh et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: